I In normal prostate cells, and at an early stage of prostate cancer, the growth of the cells is iandrogen-dependent, and can be effectively suppressed by hormonal ablation. Tumor cells linvariably become androgen resistant, however. The molecular mechanisms by which prostate cancer cells become insensitive to hormonal ablation are unknown, as yet, and several factors may be involved. Prohibitin is a potential tumor suppressor with anti-proliferative activity and regulates the progression of cells in the GI/S transition through its effects on E2F transcriptional activity. Our preliminary studies strongly suggest that prohibitin participates in the regulation of prostate cancer cell proliferation, and that androgen withdrawal or antagonists target (and require) the prohibitin/E2F axis to suppress prostate cancer cell growth. Our proposed studies will define the role of prohibitin in the response of prostate cancers to androgen withdrawal/antagonists. We will test the hypothesis that prohibitin, through its effects on the E2F transcription factors, is required for the antiproliferative effects of androgen withdrawal/antagonists on prostate cancer cells.
Specific Aims i nclude: 1) Determine the mechanism of androgen withdrawal/antagonist-induced growth repression; and, 2) Determine the regulation of prohibitin activity by androgen antagonists. We will determine the necessity of prohibitin in androgen antagonist-mediated growth arrest, using multiple prostate cell lines and diverse androgen antagonists, through colony-formation assays, cell cycle progression analyses and apoptosis analyses. We will determine the function of prohibitin in androgen antagonist-mediated transcriptional repression of E2F. We will evaluate the effects of androgen antagonists on expression of the prohibitin gene and protein and on the interactions of prohibitin and E2F. We will determine the necessity of prohibitin co-repressors, HDAC and Brm/Brg-1, in androgen withdrawal/antagonist-mediated repression of E2F transcriptional activity and growth. Our proposed studies will define a novel signaling pathway required for response to androgen withdrawal ! antagonists in prostate cells, thereby identifying new molecular targets in prostate cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
3R01CA101992-04S1
Application #
7461080
Study Section
Drug Discovery and Molecular Pharmacology Study Section (DMP)
Program Officer
Ogunbiyi, Peter
Project Start
2004-07-01
Project End
2008-04-30
Budget Start
2007-05-01
Budget End
2008-04-30
Support Year
4
Fiscal Year
2007
Total Cost
$54,031
Indirect Cost
Name
Boston University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
604483045
City
Boston
State
MA
Country
United States
Zip Code
02118
Zhu, Lijia; Chiao, Christine Y; Enzer, Katelyn G et al. (2015) SIRT1 inactivation evokes antitumor activities in NSCLC through the tumor suppressor p27. Mol Cancer Res 13:41-9
Zhu, Lijia; Qi, Ji; Chiao, Christine Ya-Chi et al. (2014) Identification of a novel polyprenylated acylphloroglucinol?derived SIRT1 inhibitor with cancer?specific anti-proliferative and invasion-suppressing activities. Int J Oncol 45:2128-36
Lovaas, Jenna D; Zhu, Lijia; Chiao, Christine Y et al. (2013) SIRT1 enhances matrix metalloproteinase-2 expression and tumor cell invasion in prostate cancer cells. Prostate 73:522-30
Moore, Robert L; Faller, Douglas V (2013) SIRT1 represses estrogen-signaling, ligand-independent ER?-mediated transcription, and cell proliferation in estrogen-responsive breast cells. J Endocrinol 216:273-85
Moore, R L; Dai, Y; Faller, D V (2012) Sirtuin 1 (SIRT1) and steroid hormone receptor activity in cancer. J Endocrinol 213:37-48
Byles, V; Zhu, L; Lovaas, J D et al. (2012) SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis. Oncogene 31:4619-29
(2011) Retraction. Requirement for chromatin-remodeling complex in novel tumor suppressor HIC1-mediated transcriptional repression and growth control. Oncogene 30:4374
Boosalis, Michael S; Castaneda, Serguei A; Trudel, Marie et al. (2011) Novel therapeutic candidates, identified by molecular modeling, induce ?-globin gene expression in vivo. Blood Cells Mol Dis 47:107-16
Byles, Vanessa; Chmilewski, Laura K; Wang, Joyce et al. (2010) Aberrant cytoplasm localization and protein stability of SIRT1 is regulated by PI3K/IGF-1R signaling in human cancer cells. Int J Biol Sci 6:599-612
Lambert, James R; Eddy, Vikram J; Young, Christian D et al. (2010) A vitamin D receptor-alkylating derivative of 1?,25-dihydroxyvitamin D3 inhibits growth of human kidney cancer cells and suppresses tumor growth. Cancer Prev Res (Phila) 3:1596-607

Showing the most recent 10 out of 18 publications